The Medicines Company (NASDAQ:MDCO) Weekly Ratings as of May 17, 2018

May 17, 2018 - By Robert Reynolds

The Medicines Company (NASDAQ:MDCO) Corporate Logo
Big Money Sentiment increased to 1.25 in 2017 Q4. It has change of 0.47, from 2017Q3’s 0.78. The ratio is positive due to The Medicines Company positioning: 26 sold and 51 reduced. 28 funds took positions and 68 increased positions. Investors holded 85.15 million in 2017Q3 but now own 89.44 million shares or 5.03% more.
Mutual Of America Mgmt Ltd Llc invested in 59,059 shs. Riverhead Mgmt Limited Liability Co has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Wellington Gru Llp has invested 0.06% in The Medicines Company (NASDAQ:MDCO). Kbc Grp Nv holds 51,830 shs. Rhumbline Advisers stated it has 0.01% in The Medicines Company (NASDAQ:MDCO). Schwab Charles Inv Management has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Financial Bank Of America Corp De invested 0% of its capital in The Medicines Company (NASDAQ:MDCO). Employees Retirement Association Of Colorado has invested 0% in The Medicines Company (NASDAQ:MDCO). Ny State Common Retirement Fund has 0.01% invested in The Medicines Company (NASDAQ:MDCO). Blackrock holds 0.01% of its capital in The Medicines Company (NASDAQ:MDCO) for 9.68 million shs. The Massachusetts-based Putnam Investments Limited Liability has invested 0.13% in The Medicines Company (NASDAQ:MDCO). Artal Grp Sa accumulated 200,000 shs. Sector Pension Board accumulated 40,317 shs. Ls Inv Advisors Ltd Limited Liability Company accumulated 2,145 shs. Principal Fincl Grp has 499,984 shs.

The Medicines Company registered $783,400 net activity with 1 buy and 3 selling transactions since December 7, 2017. ESHELMAN FREDRIC N bought $5.31 million worth of stock. On Wednesday, March 21 CROUSE WILLIAM had sold 7,500 shs worth $241,950. On Friday, December 15 MEANWELL CLIVE also sold $3.71M worth of The Medicines Company (NASDAQ:MDCO).

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

In total 3 analysts cover Medicines Co (NASDAQ:MDCO). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 6 are the (NASDAQ:MDCO)’s analyst reports since November 29, 2017 according to StockzIntelligence Inc. On Thursday, March 22 the stock has “Buy” rating by Oppenheimer. On Wednesday, November 29 Oppenheimer upgraded The Medicines Company (NASDAQ:MDCO) to “Buy” rating. The stock rating was maintained by Oppenheimer with “Buy” on Monday, January 15. In Monday, January 22 report Citigroup upgraded it to “Buy” rating and $40.0 target. On Thursday, February 22 the firm has “Hold” rating given by Oppenheimer. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain
29/11/2017 Broker: Oppenheimer Rating: Buy New Target: $50.0 Upgrade

The stock increased 0.22% or $0.07 during the last trading session, touching $32.2.Currently The Medicines Company is downtrending after 34.73% change in last May 17, 2017. MDCO has 288,319 shares volume. MDCO underperformed the S&P500 by 46.28%.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is worth $2.37 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Last it reported negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news published briefly go to: Streetinsider.com, Fool.com, Seekingalpha.com, Fool.com or Streetinsider.com. The titles are as follows: “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” published on May 07, 2018, “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” on May 17, 2018, “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” with a publish date: April 25, 2018, “Alnylam Looks Forward” and the last “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” with publication date: May 15, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.